EP 4376834 A1 20240605 - NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
Title (en)
NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS
Title (de)
NEUE SPIROPYRROLIDIN-ABGELEITETE ANTIVIRALE MITTEL
Title (fr)
NOUVEAUX AGENTS ANTIVIRAUX DÉRIVÉS DE SPIROPYRROLIDINE
Publication
Application
Priority
- US 202163227206 P 20210729
- US 202117479248 A 20210920
- US 202263324367 P 20220328
- US 2022024772 W 20220414
Abstract (en)
[origin: CA3173702A1] The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
IPC 8 full level
A61K 31/404 (2006.01); A61P 31/14 (2006.01); C07D 487/10 (2006.01)
CPC (source: EP IL KR)
A61K 31/407 (2013.01 - KR); A61P 11/00 (2018.01 - KR); A61P 31/14 (2018.01 - EP IL KR); C07D 487/10 (2013.01 - EP IL KR); C07D 487/20 (2013.01 - EP IL KR); C07D 519/00 (2013.01 - EP IL)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
AU 2022319598 A1 20240208; CA 3173702 A1 20230129; EP 4376834 A1 20240605; IL 310246 A 20240301; JP 2024529476 A 20240806; KR 20240044452 A 20240404; MX 2024001377 A 20240308
DOCDB simple family (application)
AU 2022319598 A 20220414; CA 3173702 A 20220414; EP 22850031 A 20220414; IL 31024624 A 20240118; JP 2024505183 A 20220414; KR 20247006429 A 20220414; MX 2024001377 A 20220414